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Aims: To evaluate clinical benefit of neonatal screening for CF (NS) compared to 
traditional diagnosis on clinical symptoms (CS). 
Methods: Data come from questionnaires collected each year since 1992 by the 
French CF registry (ONM). This study analyses data for patients aged 6 during the 
studied years (1999 to 2001: children born between 1993 and 1995). Data will be 
completed with data from years 2002-2003. 
Results: Results are based on 308 children of which 70 NS, 59 meconium ileus, 179 
CS divided into 3 categories • 54 early diagnosis (before 3 months), 82 diagnosis 
between 3 and 42 months, 43 late (after 42 months). These numbers increase to 566 
after adding 2002 and 2003 data. Nebulised therapy and Pseudomonas eruginosa 
colonisation at age 7 show a significant distribution difference between differents 
types of diagnosis. No difference is observed on other criteria (like Zscore for size 
and weight, FEV1 etc.) 
Conclusion: Clinical 
benefit of NS is difficult 
to prove. The difference 
in P. aeruginosa colon- 
isation between NS and 
CS at age 7 needs to be 
confirmed on a larger 
scale, but emphasizes 
the importance of early 
diagnosis and treatment 
of P. aeruginosa colon- 
i sa t ion .  7 year l i fe  
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Clinical manifestations at diagnosis: a study of CFTR mutations 
based on the French Cystic Fibrosis Registry 
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Cystic fibrosis (CF) presents in many different ways and various clinical signs 
evoke the diagnosis of CE The purpose of this study was to determine the 
frequencies of different CFTR mutations following the diagnosis based on some 
specific signs among patients identified in the French CF Registry. We extracted 
from the 2002 enquiry (3906 registered patients) data pertaining to clinical signs 
present at diagnosis: dehydration, diarrhea, growth retardation, rectal prolapse, 
respiratory manifestations, nasal polyposis, sterility and meconium ileus. 
We used a chi-square test to assess the significance of the differences between the 
38 CFTR mutations counted at least 10 times in the registry in 2002 with that 
observed in the population presenting each of the clinical signs studied. The 
significant level was set at p < 0.05. 
Mutations such as 2789+5G->A, 3272-26A->G, 3849+10kbC->T, R l l7H and 
R334W were less prevalent among patients in whom meconium ileus and/or 
diarrhea was present, but more prevalent among those with nasal polyposis and/or 
sterility; the contrary was true for the zXF508 mutation. Other mutations were 
preferentially associated with more specific signs. The 621+lG->T and 3905insT 
alleles were more prevalent among patients diagnosed because of dehydration and 
rectal prolapse respectively. The frequency of AI507 was increased in meconium 
ileus but that of G551D was decreased. 
In conclusion, as expected, "severe" mutations were more prevalent in CF patients 
diagnosed because of pancreatic manifestions (that is at a younger age) whereas 
"mild" mutations were more frequent in patients with a delayed diagnosis 
ascertained by nasal polyposis and sterility. 
Supported by " Vaincre la Mucoviscidose ". 
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L. Dracea, L. Sotiriade 
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Introduction: Despite recent improved survival, CF remains a life limiting 
condition. Early intervention and proper care are the keys of successful treatment. 
Aim: To assess the impact of an educational program for medical staff on 
improvement of outcomes of CF patients. 
Methods: We correlated the assessment of outcomes for 17 CF patients admitted 
over a 5 year period in a Children's Hospital with the directories of an educational 
based program started in 2001 meant to improve diagnosis and follow up. We 
evaluated the associated risk factors and specific interventions for two categories of 
patients: group A (nl0) with poor socioeconomic status and group B (n7) with 
normal social insertion. Access to medical care was identical for both groups. 
Results: Even age at diagnosis in group A (mean: 4.7 months) was lower compared 
to group B (mean: 5.5 years), more aggressive treatment and nutrition, 
physiotherapy and disease related education was needed. Poorer outcomes were 
reported and 50% of patients died under the age of 1 year in first group. Growth 
failure at diagnosis, frequent pulmonary exacerbations, reduced level of 
understanding the chronic pattern of disease were the main risk factors identified in 
this group. Late diagnosis was an important marker for inomogeneity of pulmonary 
outcomes in group B. There was a wide variability in the progression of disease in 
both groups, as reflected in the distribution of age at diagnosis. 
Conclusions: CF patients require more health care attention than other chronically 
ill patients, even more when socioeconomic status represents a marker of increased 
risk for adverse outcomes. Controlled therapeutic intervention and specific 
education may improve decline of lung function and provide better outcomes when 
appropriate care in organized and staffed units is provided. 
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Carboxy-gammaglutamic acid deficient prothrombin (PIVKA-II) was previously 
shown to be a marker of pancreatic insufficiency. Factor VII activity is also vitamin 
K dependent and could be a more sensitive marker due to its very short half-life. 
The aim of this study is to evaluate Factor VII activity and antigen assays in 
detection of pancreatic insufficiency in pediatric CF. Pediatric CF patients (n=8) 
were recruited prior to treatment, controls (n=25). Factor VII activity, Factor VII 
antigen, 72 hr fecal fat, activated partial thromboplastin time (APTT), and 
prothrombin time (INR) were determined. Age-dependent increases in Factor VII 
activity and antigen levels were observed in the control group, so age-matched 
controls were subsequently used. Clinical diagnosis ndicated 4 CF patients had 
pancreatic sufficiency (fecal fat 4_+2 mmol/d) and 4 were pancreatic insufficient 
(fecal fat: 35 _+ 17 mmol/d). APTT and INR values for the CF groups and controls 
were compared by ANOVA and were not significantly different (P>0.05). Factor 
VII activity assay, Factor VII antigen assay and the ratio of activity to antigen 
(fraction of Factor VII decarboxylation) were compared between the control and CF 
groups by ANOVA and were not significantly different (P>0.05). Conclusions: (1) 
This pilot study did not find any evidence that Factor VII activity, antigen or the 
ratio of activity to antigen to predict pancreatic insufficiency. (2) Age-matched 
controls are required to study Factor VII activity and antigen levels in early 
childhood. 
